Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082088 | 1.00 | HDAC6 (0.74) | HDAC6HDAC8HDAC2HDAC1MEN1 | |
| SCHEMBL5579701 | 0.86 | HDAC6 (0.81) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5079002 | 0.85 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1MEN1 | |
| SCHEMBL5078998 | 0.85 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1MEN1 | |
| SCHEMBL5081596 | 0.82 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5579372 | 0.82 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5077671 | 0.82 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5077668 | 0.82 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5082166 | 0.80 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL5078399 | 0.80 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940805-A1 | BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-07-09 | — | — | EP | claimed |
| WO-2007022638-A1 | BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-03-01 | — | — | WO | claimed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | HDAC6 24/4885HDAC8 9/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.